CombiPatch Reviews: What Women Report, What Trials Show and Who It Fits

By The HRT Index Editorial Team · Editorial research — not medically reviewed · Last verified October 2026

CombiPatch reviews lean positive: on Drugs.com, CombiPatch averaged 7.1 out of 10 from 66 reviews when we checked on October 30, 2026. Women most often praise quick relief from hot flashes and poor sleep. The most common complaints are bleeding or spotting, skin reactions to the adhesive, and cost. The clinical trials back up both sides.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified · Last verified October 2026

• What we read: the current CombiPatch prescribing information and patient information on DailyMed, including its clinical trial and side effect tables; the 66-review CombiPatch page on Drugs.com, plus a theme-by-theme read of the 25 reviews it displayed; three published CombiPatch trials (Archer 1999, Notelovitz 2000 and Adler 2005); the FDA's November 2025 request to change menopause hormone therapy labels, its February 2026 approval announcement and its list of updated labels; The Menopause Society's 2022 hormone therapy position statement; and the Climara Pro prescribing information. Every source is listed at the bottom with the date we read it.
• What we did not do: we did not use CombiPatch ourselves, contact reviewers, examine anyone or speak with a clinician for this page. We didn't write or edit any review, and we don't publish star ratings of our own. This is editorial research, not medical review, and not advice for your situation.
• Commercial interest: The HRT Index may earn a commission from some providers featured through The HRT Index's Find My HRT Path tool. No drug maker or provider paid for this page or reviewed it, and we don't earn anything from CombiPatch sales. See our affiliate disclosure.
• Verification Standard: we judge online menopause care on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency and access. Our methodology explains how.

Jump to: Scorecard · What CombiPatch is · What reviews say · Does it work? · Bleeding and spotting · Skin and sticking · Other side effects · Weight, bloating and hair · Boxed warning and FDA changes · Who shouldn't use it · Using it differently · How it compares · Cost and supply · Who tends to do well · Questions to ask · Online care · FAQ · Sources

CombiPatch reviews at a glance: the scorecard

Here's the short version, built from the review data we fetched on October 30, 2026 and from the FDA label. We don't give CombiPatch a score of our own. Reviews are personal, unverified reports, so we treat them as a guide to what to ask about rather than proof of what will happen to you.

What CombiPatch is, in plain terms

CombiPatch is a prescription skin patch made by Noven that delivers two hormones at once: estradiol (an estrogen) and norethindrone acetate, a progestin. The progestin is there to protect the lining of the uterus. That's why the FDA label says CombiPatch is for a woman with a uterus, and the patient information says not to use it if you've had a hysterectomy.

Key facts from the label:

• Two strengths: 0.05/0.14 mg per day and 0.05/0.25 mg per day. Both deliver the same estradiol dose. The difference is the amount of progestin.
• How it's worn: a new patch every 3 to 4 days (twice a week), on the lower abdomen. Avoid the waistline and never put it on or near the breasts. Rotate sites so the same spot isn't used again for at least a week.
• Two ways to use it: continuously on its own (the "continuous combined" regimen), or for 14 days of a 28-day cycle after 14 days on an estradiol-only patch (the "continuous sequential" regimen). With the sequential regimen, the label says monthly withdrawal bleeding often occurs.
• What it's approved for: moderate to severe hot flashes and night sweats from menopause; moderate to severe vaginal and vulvar symptoms from menopause (the label says to consider a vaginal product first if those are your only symptoms); and low estrogen caused by hypogonadism, removal of the ovaries or primary ovarian failure.
• Storage: in the refrigerator, in its sealed pouch. Let the patch reach room temperature before you put it on.

If you want the background on the two hormones, see progestin vs progesterone and norethindrone vs micronized progesterone.

What CombiPatch reviews say: patterns from 66 ratings

On October 30, 2026, the Drugs.com CombiPatch page showed an average rating of 7.1 out of 10 from 66 reviews, with 64% of reviewers reporting a positive experience and 17% a negative one. That matches the 7.1 from 66 we recorded in our estradiol patch reviews guide earlier this month.

Drugs.com's own list of "commonly mentioned side effects" for CombiPatch was hot flashes, bleeding, anxiety, cramps, insomnia, night sweats, spotting, bloating, hair loss and vaginal issues, plus five more it didn't show.

What we found reading the reviews one by one

We read the 25 reviews the page displayed when we fetched it. They were dated from 2018 to 2025. We counted how many mentioned each theme. This is a small, self-selected sample and not a scientific measure, but it shows what people tend to write about.

The most positive reviews were about relief. Reviewers described hot flashes stopping, sleeping through the night again, a lighter mood and less anxiety. Several said they planned to stay on it long term. One reviewer wrote, "If I forget to change the sticker, those symptoms return." That matches the label: estradiol levels drop back to postmenopausal levels within 4 to 8 hours of taking a patch off.

The most negative reviews were mostly about bleeding. One reviewer who stopped after six weeks wrote that "the heavy periods every 2 weeks were not worth it."

Remember the limits. Reviews are anonymous and self-reported. We couldn't confirm anyone's dose, regimen, diagnosis or what else they were taking. People with strong experiences, good or bad, are more likely to post. The trial data below is a steadier guide to how often things happen.

The right online menopause care isn't the same for every woman — it depends on your symptoms, what you've already tried, your age, your state and your health history. Some situations belong with an in-person clinician first. Use The HRT Index's Find My HRT Path tool to explore a featured care option for your situation — and to flag when online care isn't the right starting point — before your first consult.

Find My HRT Path is free, takes about 60 seconds and doesn't ask for your email. It asks about your symptoms, what you've already tried, your age, your state and your health history. It isn't an eligibility test or a diagnosis, and it can't tell you whether CombiPatch is right for you.

Does CombiPatch work? What the trials found

The trial evidence supports the most common praise in the reviews: CombiPatch reduces hot flashes.

Hot flashes and night sweats

The label describes two 12-week trials in 332 postmenopausal women who started with about 10 to 12 hot flashes a day. Compared with placebo, both strengths cut hot flashes more:

Hot flash intensity also fell more than on placebo in both trials. All the differences from placebo were statistically significant. Placebo also lowered hot flashes considerably, which is one reason single reviews can be hard to interpret.

A published report of the sequential trial (Notelovitz 2000) found the drop in hot flashes was already significant by the second week. In a separate 12-week open-label study of 193 women using the lower-dose patch (Adler 2005), moderate to severe hot flashes fell from 4.1 a day in week 1 to 0.6 a day by week 12, and 92.4% of women said they were satisfied or very satisfied. That study had no comparison group, so it can't separate the patch's effect from other factors.

Protecting the uterus

This is the main reason CombiPatch exists. In the year-long endometrial trials described on the label (955 women), about 1% of women on either CombiPatch strength developed endometrial hyperplasia (overgrowth of the uterine lining, which can lead to cancer). By comparison, 38% and 20% of women in the two estradiol-only patch comparison groups did. The published version of the continuous trial (Archer 1999) reported the same pattern.

That's why someone with a uterus who uses estrogen needs a progestogen. Our guide to estrogen-only vs estrogen plus progesterone explains more.

Bleeding and spotting: the most common complaint in reviews

Bleeding is the theme that splits CombiPatch reviews. Some women barely notice it. Others stop the patch because of it. The label explains why both happen.

• On the continuous regimen, the label says irregular bleeding may occur, particularly in the first six months, but generally decreases with time, often to no bleeding at all. Among women who completed the year-long trial, 53% on the 0.05/0.14 strength and 39% on the 0.05/0.25 strength had no bleeding or spotting at all in cycles 10 through 12. When women did bleed, they usually called it light, lasting about 4 days (lower dose) or 6 days (higher dose).
• On the sequential regimen, monthly withdrawal bleeding often occurs. That's expected, not a sign the patch has failed.
• The lower-progestin strength had less bleeding in the published continuous trial (Archer 1999).

Bleeding still needs attention. The patient information says to see your healthcare provider right away if you get vaginal bleeding while using CombiPatch. The Menopause Society says unscheduled bleeding that happens more than six months after starting combined hormone therapy should be investigated. Undiagnosed abnormal genital bleeding is also on the label's list of reasons not to use CombiPatch at all.

Don't decide on your own that bleeding is "just the patch," and don't adjust your dose to stop it. Several reviewers described getting checked by their doctors, which is the right move. For more, see bleeding after starting HRT and spotting on HRT, and our guide to continuous vs cyclic HRT.

Skin reactions and how well it sticks

The adhesive came up in both directions. One reviewer said she swims and soaks in the tub regularly and has "never had a patch fall off." Two others described a rash or allergic reaction, and one said she couldn't keep using it.

The label's numbers:

• Sticking: across six trials with 1,287 patients, CombiPatch completely stuck to the skin nearly 90% of the time over its 3- to 4-day wear. Fewer than 2% of patients needed to reapply or replace a patch because it lifted or came off, and 2 patients (0.2%) stopped because it wouldn't stay on.
• Skin reactions: in the year-long trials, 20% (0.05/0.14) and 23% (0.05/0.25) of women had an application-site reaction, compared with 17% on an estradiol-only patch. In the 12-week trials it was 2% and 6%, vs 4% on placebo. The label's list of these reactions includes redness, itching, rash, irritation, swelling, blistering, bruising and skin discoloration.

What the label says helps:

• Apply to a smooth, clean, dry area of the lower abdomen that isn't oily, damaged or irritated. Avoid the waistline, where clothing can rub it off.
• Press it firmly for at least 10 seconds, especially around the edges. Bathing, swimming and showering won't affect it.
• Keep it out of prolonged sun.
• Take it off slowly to avoid irritating your skin.
• If a patch falls off, reapply it. If it won't stick, put on a new one and keep to your original changing schedule.
• To throw it away, fold the sticky sides together, put it in a sturdy child-proof container and put that in the trash. Don't flush it. Used patches still contain hormones.

For more help, see estradiol patch rash, estradiol patch won't stick and how to apply an estradiol patch. Those guides cover estradiol-only patches, but most of the skin and sticking advice applies to patches in general. Check anything specific to CombiPatch with your pharmacist.

Breast pain, headaches and other side effects

The label reports side effects from two sets of trials. The table lists the ones that are most relevant to what reviewers write about. The year-long trials compared CombiPatch with an estradiol-only patch, not with placebo.

A few things stand out:

• Breast pain and painful periods were clearly more common on CombiPatch than on placebo in the 12-week trials. Breast pain was also more common with the higher-progestin strength.
• Headache happened about as often on placebo, so it's not clear CombiPatch was the cause in most cases.
• Heavy or unscheduled bleeding (vaginal hemorrhage and menorrhagia in the label's terms) was less common on CombiPatch than on the estradiol-only patch in the year-long trials: 3–6% vs 12%, and 2–5% vs 9%.

Since approval, the label also lists reports of high blood pressure, migraine, mood swings, libido changes, gallbladder problems, breast cancer and serious allergic reactions (angioedema). Because those reports are voluntary, the label says their frequency can't be estimated.

Some medicines and supplements can change how CombiPatch works. The label names St. John's wort, some seizure medicines and some anti-infectives as examples that may lower estrogen levels, possibly making it work less well or changing bleeding patterns. Tell your prescriber and pharmacist everything you take.

You can report side effects to the FDA through MedWatch or at 1-800-FDA-1088. See HRT side effects for a broader overview.

Weight, bloating and hair loss

These come up a lot in searches, so here's what the evidence says.

Does CombiPatch cause weight gain?

The evidence doesn't show that it usually does. "Weight increased" appears on the CombiPatch label only in the list of post-approval reports, which the label says can't be used to estimate frequency or prove cause. The label does say estrogen plus progestin may cause some fluid retention, and the patient information lists bloating and fluid retention among common, less serious side effects.

The Menopause Society's 2022 position statement says estrogen plus progestogen therapy "either has no effect on weight or is associated with less weight gain" in women who use it than in women who don't. It also notes that the average weight gain during midlife and the menopause transition is about 1.5 pounds a year.

None of the 25 reviews we read complained of weight gain. One reviewer said CombiPatch eased her weight gain around the middle, and another said her energy came back and she lost 20 pounds. Those are personal stories, not evidence that CombiPatch causes weight loss. See does HRT cause weight gain? for more.

Can CombiPatch cause weight loss?

There's no evidence CombiPatch is a weight-loss treatment, and it isn't approved for that. The Menopause Society says hormone therapy may help limit the build-up of belly fat during the menopause transition, but that the effect is small.

Hair loss

The CombiPatch patient information lists hair loss among its less serious but common side effects. One reviewer in our sample stopped the patch because of heavy hair shedding. Another listed hair loss as one of the menopause symptoms CombiPatch helped. If you notice new hair loss, tell your clinician, since it can have other causes too.

The boxed warning, and what the FDA's 2025–2026 changes mean for CombiPatch

Some reviewers worried about breast cancer, and one believed CombiPatch caused hers. We can't judge any one person's case. Here's what the label and the FDA say.

The current CombiPatch label still has the full boxed warning

The CombiPatch label on DailyMed (revised February 2024) carries a boxed warning for cardiovascular disorders, breast cancer, endometrial cancer and probable dementia. It's based mainly on the Women's Health Initiative (WHI), a large trial that used oral conjugated estrogens plus medroxyprogesterone acetate, not CombiPatch. The label says that, without comparable data, the risks should be assumed to be similar for other estrogen and progestin products.

In the WHI estrogen-plus-progestin study (average age 63), the label reports these extra events per 10,000 women each year compared with placebo: 7 more heart disease events, 8 more strokes, 10 more blood clots in the lungs and 8 more invasive breast cancers. It also reports 6 fewer colorectal cancers and 5 fewer hip fractures.

What the FDA changed

On November 10, 2025, the FDA asked makers of menopause hormone therapy to change their labels. For all products, it asked them to take language about cardiovascular disease, breast cancer and probable dementia out of the boxed warning, and to remove the advice to use the lowest dose for the shortest time. Cardiovascular and breast cancer warnings stay in the body of the label. For systemic products, the FDA also asked for a note that starting hormone therapy can be considered for moderate to severe hot flashes in women under 60 or within 10 years of menopause.

On February 12, 2026, the FDA announced it had approved the first updated labels. As of October 30, 2026, CombiPatch was not on the FDA's list of products with updated prescribing information, and the DailyMed label still showed the older boxed warning. Climara Pro wasn't on the list either. Vivelle-Dot and Prometrium, which some women use together instead of CombiPatch, were.

What that means for you

The FDA's November 2025 request covers all menopause hormone therapy products, but CombiPatch's label hadn't been updated on the FDA's list when we checked. Until it is, its label still shows the older boxed warning. The Menopause Society's 2022 statement says that for women under 60 or within 10 years of menopause onset who have no contraindications, "the benefit-risk ratio is favorable" for treating bothersome hot flashes and preventing bone loss. It also says the balance appears less favorable for women who start more than 10 years after menopause or after age 60.

The Menopause Society describes breast cancer with combined hormone therapy as a rare risk for women under 60, and says risks depend on the type, dose, duration of use, route and timing of hormone therapy. How that applies to you is a conversation for your clinician. Our guides to HRT and breast cancer risk and the menopause hormone therapy safety update go further.

The label also says to have a breast exam and pelvic exam each year, keep up with mammograms, and check in with your clinician every 3 to 6 months about whether you still need treatment.

Who shouldn't use CombiPatch

According to the label, CombiPatch shouldn't be used by anyone who has:

• Undiagnosed abnormal genital bleeding
• Breast cancer now, in the past, or suspected
• A known or suspected estrogen-dependent cancer
• A blood clot in the legs or lungs (DVT or PE), now or in the past
• A stroke or heart attack, now or in the past
• Liver disease or reduced liver function
• Protein C, protein S or antithrombin deficiency, or another known clotting disorder
• A known or suspected pregnancy
• A past allergic reaction, angioedema or anaphylaxis to CombiPatch

The patient information also says not to use CombiPatch after a hysterectomy, since you don't need a progestin without a uterus. If surgery is planned that raises your clot risk, the label says to stop estrogen 4 to 6 weeks beforehand if that's feasible. Ask your surgeon and prescriber.

If you're not sure where you stand, see who should not take HRT and HRT contraindications. For hot flash options without hormones, see nonhormonal options.

Reviews that describe using CombiPatch differently from the label

A few reviewers described changing how they used the patch: cutting off a sliver each month to taper, using half a patch, or wearing one patch a week instead of two. One said her symptoms came back after she cut the patch down.

The label says to change CombiPatch twice a week (every 3 to 4 days) and to use it "exactly as your healthcare provider tells you." Changing how often you wear it, or cutting it, changes the hormones you get, including the progestin that protects your uterus. If you want to lower your dose or stop, ask your prescriber about a safe plan. See can you cut an estradiol patch? and stopping HRT side effects.

If you forget to change a patch, the label says to put on a new one as soon as you can. Stopping or forgetting a patch can cause spotting or bleeding, and your symptoms may come back.

How CombiPatch compares with other combined options

Many women who read CombiPatch reviews are deciding between it and another way to get estrogen plus a progestogen. Here's how the main options compare on the facts from their labels and the FDA's list.

We cover these choices in depth in CombiPatch vs Climara Pro and CombiPatch vs estradiol patch and progesterone. For estradiol-only patch brands, see estradiol patch reviews.

Cost, coverage and supply: what reviewers run into

Cost or coverage came up in 4 of the 25 reviews we read. One reviewer said she went off CombiPatch after retiring because Medicare didn't cover it and she couldn't afford it, and planned to try a separate estrogen patch and progesterone pill instead. One 2020 review described a back order.

We don't cover prices on this page because they change often and we track them separately:

• CombiPatch cost without insurance
• Does insurance cover CombiPatch?
• Does Medicare cover CombiPatch?
• CombiPatch savings card
• CombiPatch online prescription, including current supply

Who tends to do well on CombiPatch, and who struggles

Reviews can't predict how you'll respond, but together with the label they point to some patterns.

CombiPatch may suit women who:

• Still have a uterus and need estrogen plus a progestogen
• Prefer one patch to a patch plus a pill
• Are comfortable changing a patch twice a week
• Want a skin patch rather than a pill, which you can read more about here

Reviewers who struggled most often:

• Had bleeding that didn't settle, or that they found too heavy to put up with
• Reacted to the adhesive
• Couldn't afford it or couldn't get it covered
• Were very worried about breast cancer risk

If those sound like you, there are other options, including different progestogens, a different patch or a nonhormonal treatment. A clinician can help you weigh them.

Questions to ask your clinician about CombiPatch

1. Is CombiPatch a good fit given my age, how long it's been since menopause and my health history?
2. Should I use the continuous or the sequential regimen, and which strength?
3. What bleeding should I expect, and when should I call you about it?
4. If I react to the adhesive, what should I try first?
5. How will we check how it's working, and how often will we review whether I still need it?
6. Could any of my other medicines or supplements interact with it?
7. If CombiPatch isn't covered or isn't available, what would you suggest instead?
8. If I want to stop, how should I do it?

Can you get CombiPatch through online menopause care?

Online menopause services can prescribe FDA-approved patches, and CombiPatch is one option. Which product fits depends on you. Here's how our five pillars apply:

• Clinical legitimacy: a licensed clinician should take a full history before prescribing, including whether you have a uterus, any abnormal bleeding, and any history of clots, stroke, heart disease, liver disease or breast cancer.
• Care quality: look for clear follow-up, a plan for what to do about unexpected bleeding, and a route to in-person care when you need it.
• Medication fit: a good service can offer more than one combined option, including separate estradiol and progesterone, so you're not locked into one product.
• Price transparency: you should know what visits, refills and the medicine itself are likely to cost before you start.
• Access: you'll still need yearly breast and pelvic exams and mammograms, and some bleeding problems need an in-person exam or ultrasound.

See is online HRT safe? for how to judge a service.

Frequently asked questions

Are CombiPatch reviews mostly good or bad?

Mostly good. On October 30, 2026, CombiPatch averaged 7.1 out of 10 from 66 reviews on Drugs.com, with 64% positive and 17% negative. The most common praise is relief from hot flashes and better sleep. The most common complaint is bleeding or spotting.

How long does CombiPatch take to work?

In the sequential trial, hot flashes fell significantly compared with placebo by the second week, and the trials ran 12 weeks in total. Some reviewers described relief within days. A couple said it took about four weeks. Give your clinician feedback if you don't see a change.

Does the bleeding on CombiPatch stop?

On the continuous regimen it often does. The label says irregular bleeding is most likely in the first six months and generally decreases. In the year-long trial, 53% (lower dose) and 39% (higher dose) had no bleeding at all by cycles 10 to 12. On the sequential regimen, a monthly bleed is expected. Tell your clinician about any bleeding.

Does CombiPatch cause weight gain?

Not usually. "Weight increased" appears on the label only among post-approval reports, and The Menopause Society says estrogen plus progestogen therapy either has no effect on weight or is linked to less weight gain. Some fluid retention and bloating can happen.

Does CombiPatch cause hair loss?

It can. The patient information lists hair loss among the less serious but common side effects. Tell your clinician if you notice new shedding.

Is CombiPatch bioidentical?

Partly. The estradiol in CombiPatch is 17β-estradiol, the same estrogen the ovaries make. The progestin, norethindrone acetate, is synthetic, not progesterone. See progestin vs progesterone.

Can I use CombiPatch if I've had a hysterectomy?

No. The patient information says not to use CombiPatch if you've had your uterus removed, because without a uterus you don't need a progestin. Ask your clinician which product would suit you instead.

Can Find My HRT Path tell me if CombiPatch is right for me?

No. Find My HRT Path asks about your symptoms, what you've tried, your age, your state and your health history, and points you to a featured care option or flags when online care isn't the right start. Only a clinician who knows your history can decide on a prescription.

The bottom line

CombiPatch reviews are mostly positive. Many women say it relieved hot flashes, night sweats and poor sleep, sometimes within days, and the trials agree that it works and protects the uterus. The trade-offs show up just as clearly in the reviews and the label: bleeding or spotting, especially in the first six months; skin reactions in some users; breast tenderness; and a cost that some reviewers couldn't keep up with. The label still carries the older boxed warning, and it isn't for anyone with a history of breast cancer, blood clots, stroke, heart attack, liver disease or unexplained bleeding, or anyone without a uterus. Use the reviews to plan your questions, and decide with your clinician.

If you're weighing CombiPatch against other ways to treat menopause symptoms, Find My HRT Path can help you see what fits and flag when in-person care should come first.

Related reading

• Estradiol patch reviews
• CombiPatch vs Climara Pro
• CombiPatch vs estradiol patch and progesterone
• CombiPatch cost without insurance
• Bleeding after starting HRT
• Veozah reviews
• HRT side effects
• Who should not take HRT

Sources

All sources were read on October 30, 2026.

1. CombiPatch (estradiol/norethindrone acetate transdermal system) prescribing information and patient information, Noven Pharmaceuticals, revised February 2024. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66
2. CombiPatch user reviews and ratings. Drugs.com. https://www.drugs.com/comments/estradiol-norethindrone/combipatch.html
3. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. Obstetrics & Gynecology, 1999;94(4):498–503. https://pubmed.ncbi.nlm.nih.gov/10511348/
4. Notelovitz M, Cassel D, Hille D, et al. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. American Journal of Obstetrics and Gynecology, 2000;182(1 Pt 1):7–12. https://pubmed.ncbi.nlm.nih.gov/10649149/
5. Adler G, Young D, Galant R, et al. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. Gynecologic and Obstetric Investigation, 2005;59(4):212–219. https://pubmed.ncbi.nlm.nih.gov/15753617/
6. US Food and Drug Administration. FDA requests labeling changes related to safety information to clarify benefit/risk considerations of menopausal hormone therapy (November 10, 2025). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations
7. US Food and Drug Administration. FDA approves labeling changes for menopausal hormone therapy products (February 12, 2026). https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
8. US Food and Drug Administration. Menopausal hormone therapies: updated prescribing information. https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information
9. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022;29(7):767–794. https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
10. Climara Pro (estradiol and levonorgestrel transdermal system) prescribing information, Bayer HealthCare Pharmaceuticals. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=184d3092-7fc6-4375-816b-1ab06bb99cfd
11. US Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

This page is for education only and is not medical advice. It doesn't replace an examination, diagnosis or treatment plan from a clinician who knows your health history. If you have unexpected vaginal bleeding, a new breast lump, a sudden severe headache, vision or speech changes, or severe pain in your chest or legs while using CombiPatch, contact a clinician promptly or call 911 in an emergency.